Link to site

Elthera AG is developing antibodies against the novel target L1CAM, an adhesion molecule whose expression is strongly correlated with an aggressive tumour phenotype and poor prognosis in various types of cancer. Inhibition of L1CAM targets many mechanisms of tumour progression such as resistance to chemotherapy, escape from immunological control, formation of new blood vessels, tumour growth and metastases formation.

This therapy will be developed using the established approach of humanized antibodies, thus allowing fast development into clinical studies without the potential risk of other formats. By combining targeted anti-L1CAM therapy with companion diagnostics, Elthera AG is aiming at providing new personalized treatment options for patients with the most aggressive malignancies.